02131nam a2200397 i 4500001001300000003000600013005001700019007001400036008004100050040002800091042000800119043001200127050002300139074001900162086002300181088009000204110013500294245026400429264006000693300002700753336002600780337002700806338003100833338003100864500003600895500010800931504004101039500002601080500002501106533010701131650003301238650004601271655003301317776020001350776018301550ocn974947661OCoLC20170418095521.0he bmb024bbca170310s2016    dcu     bb   f000 0 eng c  aGPObengerdacGPOdMvI  apcc  an-us---14aKF27b.E5514 2016b  a1019-B-01 (MF)0 aY 4.C 73/8:114-142  aSerial no. 114-142 (United States. Congress. House. Committee on Energy and Commerce)1 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Commerce, Manufacturing, and Trade,eauthor.14aThe pet medications industry :bissues and perspectives : hearing before the Subcommittee on Commerce, Manufacturing, and Trade of the Committee on Energy and Commerce, House of Representatives, One Hundred Fourteenth Congress, second session, April 29, 2016. 1aWashington :bU.S. Government Publishing Office,c2016.  aiii, 94 pages ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  amicrofichebhe2rdacarrier  aShipping list no.: 2016-0279-M.  aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  aIncludes bibliographical references.  a"Serial No. 114-142."  aCRDP Program record.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2016]e2 microfiches : negative. 0aPet medicinezUnited States. 0aPetsxDiseasesxTreatmentzUnited States. 7aLegislative hearings.2lcgft08iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Commerce, Manufacturing, and Trade.tPet medications industryw(DLC) 2016436149w(OCoLC)96037277608iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Commerce, Manufacturing, and Trade.tPet medications industryw(OCoLC)959928473